The specific aim of this study is to evaluate the efficacy and tolerability of a stimulant (lisdexamfetamine) in the adjunctive treatment of bipolar disorder.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
25
oral; 20-70mg/day
oral; 20-70mg/day
Lindner Center of HOP
Mason, Ohio, United States
Change in the Montgomery-Asberg Depression Rating Scale
Efficacy will be assessed by measuring the baseline-to-endpoint change in the Montgomery-Asberg Depression Rating Scale (MADRS)
Time frame: 30-36 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.